BURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. (more…)

BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts.

(more…)

BURLINGTON, Mass. (September 4, 2025) – Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders.

(more…)

BURLINGTON, Mass. (September 3, 2025) – Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025.

(more…)

BURLINGTON, Mass., June 30, 2025 — Bone Biologics Corporation (“Bone Biologics” or the “Company”)
(Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants have an exercise price of $4.00 per share, are exercisable immediately upon issuance and will expire five years after the date of issuance, and the Series E short-term warrants have an exercise price of $4.00 per share, are exercisable immediately upon issuance and will expire 18 months after the date of issuance.

(more…)

BURLINGTON, Mass. – June 27, 2025 – Bone Biologics Corporation (“Bone Biologics” or the “Company)
(NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein.

(more…)

BURLINGTON, Mass., June 27, 2025 — Bone Biologics Corporation (“Bone Biologics” or the “Company”)

(Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and will expire five years after the date of issuance, and the Series E short-term warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and will expire 18 months after the date of issuance. The closing of the offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions.

(more…)

BURLINGTON, Mass. (June 26, 2025) — Bone Biologics Corporation (“Bone Biologics” or the “Company”)

(Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market. Bone Biologics is now in compliance with all applicable listing standards and its common stock will continue to be listed on the Nasdaq Capital Market.

(more…)

BURLINGTON, Mass. (October 21, 2024) – Bone Biologics Corporation (“Bone Biologics” or the “Company”)
(Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four.

 

(more…)

BURLINGTON, Mass.–(BUSINESS WIRE)–— Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics’ company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern time. The presentation will be available on the company’s website for a period of time here.

BURLINGTON, Mass.–(BUSINESS WIRE)–— Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-276771).

BURLINGTON, Mass. (June 17, 2024) – Bone Biologics Corporation (“Bone Biologics” or the “Company”)
(Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, the Company’s president and chief executive officer, and Deina Walsh, chief financial officer, will be interviewed by Zacks Small-Cap Research analyst Brad Sorensen, CFA in a “CEO Chat” on June 20th at the Life Science Investor Forum with Virtual Investor Conference hosted by VirtualInvestorConferences.com

 

(more…)

Reminder: Management “CEO Chat” with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time

BURLINGTON, Mass. (June 20, 2024) — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration. (more…)

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants have an exercise price of $2.43 per share, are exercisable immediately upon issuance and will expire five years after the date of issuance.

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $2.43 per share, will be exercisable immediately upon issuance and will expire five years after the date of issuance. The closing of the offering is expected to occur on or about March 6, 2024, subject to the satisfaction of customary closing conditions.

BURLINGTON, Mass., January 11, 2024–(BUSINESS WIRE)–Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors.

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share. In a concurrent private placement, the Company also issued and sold unregistered warrants to purchase up to an aggregate of 1,139,063 shares of its common stock. The unregistered warrants have an exercise price of $0.52 per share and are exercisable upon issuance and have a term of five and one-half years from the date of issuance.

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the company has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,139,063 shares of its common stock. The offering is expected to close on or about November 20, 2023, subject to the satisfaction of customary closing conditions.

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the pricing of an underwritten public offering of common stock.

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia.

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces the pricing of an underwritten public offering of 3,777,778 units of securities at an offering price of $1.35 per unit, for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

Each unit consists of: (i) one share of common stock; (ii) one Series A warrant to purchase one share of common stock at an exercise price equal to $1.62 per share; (iii) one Series B warrant to purchase one share of common stock at an exercise price equal to $1.35 per share; and (iv) one Series C warrant, to purchase one share of common stock at an exercise price equal to $2.16 per share. The Series C warrant can be exercised via cashless exercise upon the earlier of 15 days from the warrant issuance date or the time when $10 million of volume is traded in the common shares. The shares of common stock and the Purchase Warrants are immediately separable and will be issued separately, but will be purchased together in this offering. The warrants expire five years from the date of issuance.

In addition, Bone Biologics has granted the underwriters a 45-day option to purchase up to 566,666 additional shares of common stock and/or 566,666 additional warrants, or any combination thereof, to cover over-allotments in this offering, if any. The offering is expected to close on or about October 11, 2022, subject to customary closing conditions.

WallachBeth Capital, LLC is acting as the sole book-running manager for the offering.

This offering is being made pursuant to an effective registration statement on Form S-1 (No. 333-267588) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on October 6, 2022. A final prospectus describing the terms of the proposed offering will be filed with the SEC and may be obtained, when available, via the SEC’s website at www.sec.gov or from WallachBeth Capital, LLC, via email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking groundbreaking work with select strategic partners, that build on the preclinical research of the Nell-1 protein. Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.

Forward-looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘’believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop our lead product NELL-1 and other proposed products, its ability to obtain patent protection for its technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Form 10-K for the year ended December 31, 2021 and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contacts

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company’s president and chief executive officer, has been invited to present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28 – 30, 2022. A pre-recorded presentation will be available for 72 hours beginning Monday, March 28^th at 9:00 a.m. Eastern time. Interested parties may access a webcast of the presentation on the investor relations section of the Company’s website and at this link.

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has entered into a supply agreement with MTF Biologics for demineralized bone matrix (DBM). MTF Biologics is a global nonprofit organization that provides one of the orthopedic industry’s largest portfolios of allograft tissue.

Bone Biologics Corp. (NASDAQ: BBLG) a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company’s president and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference being held January 10 – 13, 2022. A pre-recorded presentation will be available beginning Monday, January 10 at 7:00 a.m. Eastern time. Interested parties may access a webcast of the presentation on the investor relations section of the Company’s website and at this link.

Bone Biologics Corp. (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its underwritten public offering of 1,510,455 units of securities at an offering price of $5.25 per unit, for total gross proceeds of $7.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for spine fusion, trauma, and osteoporosis markets, has announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.

Bone Biologics Corp. (OTCQB:BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it received Human Research Ethics Committee (HREC) approval on March 20, 2019, for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX®) in 30 patients in Australia. The pilot study will evaluate the safety and effectiveness of NB1 in adult subjects with degenerative disc disease (DDD) at one level from L2-S1, who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level who undergo transforaminal lumbar interbody fusion (TLIF).

Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of $5.9 million funding; $3.9 million in equity and a $2 million credit facility.

Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of $500,000 funding with Orthofix Holding, Inc.

Bone Biologics Corp. (OTC QB: BBLG), a developer of orthobiologic products for the spinal fusion, trauma and osteoporosis markets, today has announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. In addition, rhNELL-1 was shown to be well tolerated and there were no findings of inflammation.

BURLINGTON, Mass., August 23, 2017 — Bone Biologics Corp (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it has expanded its Field of Use definition of the license agreement with the UCLA Technology Development Group on behalf of UC Regents for NELL-1. Additionally, Bone Biologics has entered into an exclusive license agreement with the UCLA Technology Development Group on behalf of UC Regents for the worldwide application of the NELL-1 protein for both osteoporosis and trauma through a technology transfer.

Bone Biologics (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of a $1.4 million funding round with Musculoskeletal Transplant Foundation and Hankey Capital, LLC.

Bone Biologics Corp. (OTCQB: BBLG) announced that Bret Hankey has joined the company’s board of directors.

Bone Biologics Corporation (OTCQB: BBLG) announced today that it has commenced a private offering of up to $10,000,000 of its securities. The securities will initially only be offered to persons who are either stockholders of the company or who are “accredited investors,” as defined in Regulation D under the Securities Act of 1933, as amended (the “Securities Act”).

Bone Biologics Corporation announced the engagement of Scott D. Boden, MD as Chief Medical Advisor. Dr. Boden is a tenured Professor of Orthopaedic Surgery at the Emory University School of Medicine and serves as the Director of the Emory Orthopaedics & Spine Center, Vice Chair of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs. He is also the Clinical Director of the Whitesides Orthopedic Research Laboratory.

Bone Biologics (OTCQB: BBLG), an orthobiologic company focused on regenerative medicine, announced today the signing of an option agreement with UCLA, for an opportunity to exclusively license the use of the revolutionary bone growth factor Nell-1 in the treatment of osteoporosis.

Bone Biologics (OTCQB: BBLG), an orthobiologic company focused on regenerative medicine, announced today the completion of a $5.75 million funding round with Musculoskeletal Transplant Foundation, OrthoFix Holdings, Inc. and Hankey Capital, LLC.

EDISON, N.J., May 6, 2015 — Bone Biologics, Corp., (“Bone Biologics”) announced today the completion of a $2M funding round with Hankey Capital, LLC (“Hankey Capital”) of Los Angeles, CA. The company is developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or NELL-1) for use with patients undergoing spinal fusion.